Follow the people · Insider
Scott Bizily
Scott Bizily files insider transactions with the SEC as a chief legal officer of 4D Molecular Therapeutics (FDMT). We hold 5 disclosed purchases and sales filed since 21 June 2022, 5 of them in the last 90 days.
- Files forFDMT
- Disclosed buys and sells5 in all, 5 in the last 90 days
- Last disclosure3 September 2026
Positions held
2 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 18 June 2022 — 1 September 2026Chief Legal Officer · 4D Molecular Therapeutics (FDMT)128 Form 4 lines · source: SEC Form 4
- Filed 1 June 2023 — 8 June 2023Chief Legal and HR Officer · 4D Molecular Therapeutics (FMDT)6 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 584 shares of 4D Molecular TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- ▼ sold on the open market 584 shares of 4D Molecular TherapeuticsSEC Form 43 September 2026Common Stock · traded 1 September 2026 · filed 3 September 2026
- exercised options over 584 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 43 September 2026Stock Option (Right to Buy) · traded 1 September 2026 · filed 3 September 2026
- exercised options over 1,635 shares of 4D Molecular TherapeuticsSEC Form 417 August 2026Common Stock · traded 13 August 2026 · filed 17 August 2026
- ▼ sold on the open market 1,635 shares of 4D Molecular TherapeuticsSEC Form 417 August 2026Common Stock · traded 13 August 2026 · filed 17 August 2026
- exercised options over 1,635 shares of 4D Molecular TherapeuticsSEC Form 417 August 2026Common Stock · traded 17 August 2026 · filed 17 August 2026
- ▼ sold on the open market 1,635 shares of 4D Molecular TherapeuticsSEC Form 417 August 2026Common Stock · traded 17 August 2026 · filed 17 August 2026
- exercised options over 1,635 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 417 August 2026Stock Option (Right to Buy) · traded 13 August 2026 · filed 17 August 2026
- exercised options over 1,635 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 417 August 2026Stock Option (Right to Buy) · traded 17 August 2026 · filed 17 August 2026
- exercised options over 814 shares of 4D Molecular TherapeuticsSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
- exercised options over 5,752 shares of 4D Molecular TherapeuticsSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
- ▼ sold on the open market 6,566 shares of 4D Molecular TherapeuticsSEC Form 42 July 2026Common Stock · traded 30 June 2026 · filed 2 July 2026
- exercised options over 814 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 42 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 2 July 2026
- exercised options over 5,752 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 42 July 2026Stock Option (Right to Buy) · traded 30 June 2026 · filed 2 July 2026
- exercised options over 9,810 shares of 4D Molecular TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- ▼ sold on the open market 9,810 shares of 4D Molecular TherapeuticsSEC Form 425 June 2026Common Stock · traded 23 June 2026 · filed 25 June 2026
- exercised options over 9,810 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 425 June 2026Stock Option (Right to Buy) · traded 23 June 2026 · filed 25 June 2026
- was granted 217,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 427 March 2026Stock Option (Right to Buy) · traded 25 March 2026 · filed 27 March 2026
- was granted 217,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 427 March 2026Stock Option (Right to Buy) · traded 25 March 2026 · filed 27 March 2026
- exercised options over 1,635 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 419 December 2025Stock Option (Right to Buy) · traded 16 December 2025 · filed 19 December 2025
- exercised options over 1,635 shares of 4D Molecular TherapeuticsSEC Form 419 December 2025Common Stock · traded 16 December 2025 · filed 19 December 2025
- ▼ sold on the open market 1,635 shares of 4D Molecular TherapeuticsSEC Form 419 December 2025Common Stock · traded 16 December 2025 · filed 19 December 2025
- exercised options over 1,635 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 419 November 2025Stock Option (Right to Buy) · traded 17 November 2025 · filed 19 November 2025
- exercised options over 1,635 shares of 4D Molecular TherapeuticsSEC Form 419 November 2025Common Stock · traded 17 November 2025 · filed 19 November 2025
- ▼ sold on the open market 1,635 shares of 4D Molecular TherapeuticsSEC Form 419 November 2025Common Stock · traded 17 November 2025 · filed 19 November 2025
- exercised options over 1,084 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 427 October 2025Stock Option (Right to Buy) · traded 24 October 2025 · filed 27 October 2025
- exercised options over 1,084 shares of 4D Molecular TherapeuticsSEC Form 427 October 2025Common Stock · traded 24 October 2025 · filed 27 October 2025
- ▼ sold on the open market 2,678 shares of 4D Molecular TherapeuticsSEC Form 427 October 2025Common Stock · traded 24 October 2025 · filed 27 October 2025
- exercised options over 1,635 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 420 October 2025Stock Option (Right to Buy) · traded 16 October 2025 · filed 20 October 2025
- exercised options over 1,635 shares of 4D Molecular TherapeuticsSEC Form 420 October 2025Common Stock · traded 16 October 2025 · filed 20 October 2025
- ▼ sold on the open market 1,635 shares of 4D Molecular TherapeuticsSEC Form 420 October 2025Common Stock · traded 16 October 2025 · filed 20 October 2025
- ▼ sold on the open market 2,408 shares of 4D Molecular TherapeuticsSEC Form 414 October 2025Common Stock · traded 9 October 2025 · filed 14 October 2025
- ▼ sold on the open market 2,407 shares of 4D Molecular TherapeuticsSEC Form 426 September 2025Common Stock · traded 23 September 2025 · filed 26 September 2025
- was granted 78,500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 410 March 2025Stock Option (Right to Buy) · traded 6 March 2025 · filed 10 March 2025
- exercised options over 500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 418 September 2024Stock Option (Right To Buy) · traded 16 September 2024 · filed 18 September 2024
- exercised options over 500 shares of 4D Molecular TherapeuticsSEC Form 418 September 2024Common Stock · traded 16 September 2024 · filed 18 September 2024
- ▼ sold on the open market 500 shares of 4D Molecular TherapeuticsSEC Form 418 September 2024Common Stock · traded 16 September 2024 · filed 18 September 2024
- exercised options over 500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 421 August 2024Stock Option (Right To Buy) · traded 19 August 2024 · filed 21 August 2024
- exercised options over 500 shares of 4D Molecular TherapeuticsSEC Form 421 August 2024Common Stock · traded 19 August 2024 · filed 21 August 2024
- ▼ sold on the open market 500 shares of 4D Molecular TherapeuticsSEC Form 421 August 2024Common Stock · traded 19 August 2024 · filed 21 August 2024
- exercised options over 500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 418 July 2024Stock Option (Right To Buy) · traded 16 July 2024 · filed 18 July 2024
- exercised options over 1,250 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 418 July 2024Stock Option (Right To Buy) · traded 16 July 2024 · filed 18 July 2024
- exercised options over 500 shares of 4D Molecular TherapeuticsSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- exercised options over 1,250 shares of 4D Molecular TherapeuticsSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- ▼ sold on the open market 1,750 shares of 4D Molecular TherapeuticsSEC Form 418 July 2024Common Stock · traded 16 July 2024 · filed 18 July 2024
- exercised options over 1,996 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 415 July 2024Stock Option (Right To Buy) · traded 11 July 2024 · filed 15 July 2024
- exercised options over 1,996 shares of 4D Molecular TherapeuticsSEC Form 415 July 2024Common Stock · traded 11 July 2024 · filed 15 July 2024
- ▼ sold on the open market 1,996 shares of 4D Molecular TherapeuticsSEC Form 415 July 2024Common Stock · traded 11 July 2024 · filed 15 July 2024
- exercised options over 1,332 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 43 July 2024Stock Option (Right To Buy) · traded 1 July 2024 · filed 3 July 2024
- exercised options over 2,916 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 43 July 2024Stock Option (Right To Buy) · traded 1 July 2024 · filed 3 July 2024
- exercised options over 1,332 shares of 4D Molecular TherapeuticsSEC Form 43 July 2024Common Stock · traded 1 July 2024 · filed 3 July 2024
- exercised options over 2,916 shares of 4D Molecular TherapeuticsSEC Form 43 July 2024Common Stock · traded 1 July 2024 · filed 3 July 2024
- ▼ sold on the open market 4,248 shares of 4D Molecular TherapeuticsSEC Form 43 July 2024Common Stock · traded 1 July 2024 · filed 3 July 2024
- exercised options over 500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 420 June 2024Stock Option (Right To Buy) · traded 17 June 2024 · filed 20 June 2024
- exercised options over 1,250 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 420 June 2024Stock Option (Right To Buy) · traded 17 June 2024 · filed 20 June 2024
- exercised options over 500 shares of 4D Molecular TherapeuticsSEC Form 420 June 2024Common Stock · traded 17 June 2024 · filed 20 June 2024
- exercised options over 1,250 shares of 4D Molecular TherapeuticsSEC Form 420 June 2024Common Stock · traded 17 June 2024 · filed 20 June 2024
- ▼ sold on the open market 1,750 shares of 4D Molecular TherapeuticsSEC Form 420 June 2024Common Stock · traded 17 June 2024 · filed 20 June 2024
- exercised options over 500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 420 May 2024Stock Option (Right To Buy) · traded 16 May 2024 · filed 20 May 2024
- exercised options over 1,250 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 420 May 2024Stock Option (Right To Buy) · traded 16 May 2024 · filed 20 May 2024
- exercised options over 500 shares of 4D Molecular TherapeuticsSEC Form 420 May 2024Common Stock · traded 16 May 2024 · filed 20 May 2024
- exercised options over 1,250 shares of 4D Molecular TherapeuticsSEC Form 420 May 2024Common Stock · traded 16 May 2024 · filed 20 May 2024
- ▼ sold on the open market 1,283 shares of 4D Molecular TherapeuticsSEC Form 420 May 2024Common Stock · traded 16 May 2024 · filed 20 May 2024
- ▼ sold on the open market 467 shares of 4D Molecular TherapeuticsSEC Form 420 May 2024Common Stock · traded 16 May 2024 · filed 20 May 2024
- exercised options over 500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 418 April 2024Stock Option (Right To Buy) · traded 16 April 2024 · filed 18 April 2024
- exercised options over 1,250 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 418 April 2024Stock Option (Right To Buy) · traded 16 April 2024 · filed 18 April 2024
- exercised options over 500 shares of 4D Molecular TherapeuticsSEC Form 418 April 2024Common Stock · traded 16 April 2024 · filed 18 April 2024
- exercised options over 1,250 shares of 4D Molecular TherapeuticsSEC Form 418 April 2024Common Stock · traded 16 April 2024 · filed 18 April 2024
- ▼ sold on the open market 1,750 shares of 4D Molecular TherapeuticsSEC Form 418 April 2024Common Stock · traded 16 April 2024 · filed 18 April 2024
- exercised options over 1,332 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 43 April 2024Stock Option (Right To Buy) · traded 1 April 2024 · filed 3 April 2024
- exercised options over 2,916 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 43 April 2024Stock Option (Right To Buy) · traded 1 April 2024 · filed 3 April 2024
- exercised options over 1,996 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 43 April 2024Stock Option (Right To Buy) · traded 1 April 2024 · filed 3 April 2024
- exercised options over 1,909 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 43 April 2024Stock Option (Right To Buy) · traded 1 April 2024 · filed 3 April 2024
- exercised options over 1,332 shares of 4D Molecular TherapeuticsSEC Form 43 April 2024Common Stock · traded 1 April 2024 · filed 3 April 2024
- exercised options over 2,916 shares of 4D Molecular TherapeuticsSEC Form 43 April 2024Common Stock · traded 1 April 2024 · filed 3 April 2024
- exercised options over 1,996 shares of 4D Molecular TherapeuticsSEC Form 43 April 2024Common Stock · traded 1 April 2024 · filed 3 April 2024
- exercised options over 1,909 shares of 4D Molecular TherapeuticsSEC Form 43 April 2024Common Stock · traded 1 April 2024 · filed 3 April 2024
- ▼ sold on the open market 8,153 shares of 4D Molecular TherapeuticsSEC Form 43 April 2024Common Stock · traded 1 April 2024 · filed 3 April 2024
- exercised options over 4,342 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 429 March 2024Stock Option (Right To Buy) · traded 27 March 2024 · filed 29 March 2024
- exercised options over 1,491 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 429 March 2024Stock Option (Right To Buy) · traded 27 March 2024 · filed 29 March 2024
- exercised options over 4,342 shares of 4D Molecular TherapeuticsSEC Form 429 March 2024Common Stock · traded 27 March 2024 · filed 29 March 2024
- exercised options over 1,491 shares of 4D Molecular TherapeuticsSEC Form 429 March 2024Common Stock · traded 27 March 2024 · filed 29 March 2024
- ▼ sold on the open market 5,833 shares of 4D Molecular TherapeuticsSEC Form 429 March 2024Common Stock · traded 27 March 2024 · filed 29 March 2024
- exercised options over 500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 420 March 2024Stock Option (Right To Buy) · traded 18 March 2024 · filed 20 March 2024
- exercised options over 1,250 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 420 March 2024Stock Option (Right To Buy) · traded 18 March 2024 · filed 20 March 2024
- exercised options over 500 shares of 4D Molecular TherapeuticsSEC Form 420 March 2024Common Stock · traded 18 March 2024 · filed 20 March 2024
- exercised options over 1,250 shares of 4D Molecular TherapeuticsSEC Form 420 March 2024Common Stock · traded 18 March 2024 · filed 20 March 2024
- ▼ sold on the open market 1,750 shares of 4D Molecular TherapeuticsSEC Form 420 March 2024Common Stock · traded 18 March 2024 · filed 20 March 2024
- exercised options over 1,909 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 429 February 2024Stock Option (Right To Buy) · traded 27 February 2024 · filed 29 February 2024
- exercised options over 1,909 shares of 4D Molecular TherapeuticsSEC Form 429 February 2024Common Stock · traded 27 February 2024 · filed 29 February 2024
- ▼ sold on the open market 1,909 shares of 4D Molecular TherapeuticsSEC Form 429 February 2024Common Stock · traded 27 February 2024 · filed 29 February 2024
- exercised options over 500 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 421 February 2024Stock Option (Right To Buy) · traded 16 February 2024 · filed 21 February 2024
- exercised options over 1,250 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 421 February 2024Stock Option (Right To Buy) · traded 16 February 2024 · filed 21 February 2024
- exercised options over 500 shares of 4D Molecular TherapeuticsSEC Form 421 February 2024Common Stock · traded 16 February 2024 · filed 21 February 2024
- exercised options over 1,250 shares of 4D Molecular TherapeuticsSEC Form 421 February 2024Common Stock · traded 16 February 2024 · filed 21 February 2024
- ▼ sold on the open market 1,750 shares of 4D Molecular TherapeuticsSEC Form 421 February 2024Common Stock · traded 16 February 2024 · filed 21 February 2024
- exercised options over 1,332 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 412 February 2024Stock Option (Right to Buy) · traded 8 February 2024 · filed 12 February 2024
- exercised options over 2,916 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 412 February 2024Stock Option (Right to Buy) · traded 8 February 2024 · filed 12 February 2024
- exercised options over 1,996 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 412 February 2024Stock Option (Right to Buy) · traded 8 February 2024 · filed 12 February 2024
- exercised options over 1,332 shares of 4D Molecular TherapeuticsSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- ▼ sold on the open market 1,332 shares of 4D Molecular TherapeuticsSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- exercised options over 2,916 shares of 4D Molecular TherapeuticsSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- ▼ sold on the open market 2,916 shares of 4D Molecular TherapeuticsSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- exercised options over 1,996 shares of 4D Molecular TherapeuticsSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- ▼ sold on the open market 1,996 shares of 4D Molecular TherapeuticsSEC Form 412 February 2024Common Stock · traded 8 February 2024 · filed 12 February 2024
- was granted 130,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 413 December 2023Stock Option (Right to Buy) · traded 11 December 2023 · filed 13 December 2023
- exercised options over 3,750 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 412 June 2023Stock Option (Right to Buy) · traded 8 June 2023 · filed 12 June 2023
- exercised options over 3,750 shares of 4D Molecular TherapeuticsSEC Form 412 June 2023Common Stock · traded 8 June 2023 · filed 12 June 2023
- ▼ sold on the open market 3,750 shares of 4D Molecular TherapeuticsSEC Form 412 June 2023Common Stock · traded 8 June 2023 · filed 12 June 2023
- exercised options over 1,875 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 46 June 2023Stock Option (Right to Buy) · traded 1 June 2023 · filed 6 June 2023
- exercised options over 1,875 shares of 4D Molecular TherapeuticsSEC Form 46 June 2023Common Stock · traded 1 June 2023 · filed 6 June 2023
- ▼ sold on the open market 2,247 shares of 4D Molecular TherapeuticsSEC Form 46 June 2023Common Stock · traded 1 June 2023 · filed 6 June 2023
- exercised options over 3,750 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 425 April 2023Stock Option (Right to Buy) · traded 21 April 2023 · filed 25 April 2023
- exercised options over 3,750 shares of 4D Molecular TherapeuticsSEC Form 425 April 2023Common Stock · traded 21 April 2023 · filed 25 April 2023
- ▼ sold on the open market 3,750 shares of 4D Molecular TherapeuticsSEC Form 425 April 2023Common Stock · traded 21 April 2023 · filed 25 April 2023
- exercised options over 1,875 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 43 March 2023Stock Option (Right to Buy) · traded 1 March 2023 · filed 3 March 2023
- exercised options over 1,875 shares of 4D Molecular TherapeuticsSEC Form 43 March 2023Common Stock · traded 1 March 2023 · filed 3 March 2023
- ▼ sold on the open market 2,248 shares of 4D Molecular TherapeuticsSEC Form 43 March 2023Common Stock · traded 1 March 2023 · filed 3 March 2023
- was granted 50,000 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 414 February 2023Stock Option (Right to Buy) · traded 10 February 2023 · filed 14 February 2023
- exercised options over 1,875 shares of 4D Molecular Therapeutics (a derivative holding)SEC Form 45 December 2022Stock Option (Right to Buy) · traded 1 December 2022 · filed 5 December 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.